Renal Safety of Bowel Preparation With Polyethylene Glycol

• Status: Completed
• Trial end date: 2017-06-30
• Target enrollment: 0
• Participant gender: All

Summary

This study evaluates the changes of renal function after taking bowel cleansing agent polyethylene glycol for elective colonoscopy.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Evergreen General Hospital, Taiwan

Criteria

Inclusion Criteria:

• Subjects 40 yrs of age or older scheduled for elective colonoscopy.

Exclusion Criteria:

• Severely reduced kidney function (eGFR] <30 mL/min/1.73 m2)

• Serum electrolyte abnormalities at screening

• Uncontrolled congestive heart failure (American Heart Association Classification III or IV)

• Unstable angina

• Untreated dysrhythmia

• Myocardial infarction, percutaneous transluminal coronary angioplasty, or coronary artery bypass graft surgery within the previous 3 months

• Ascites

• Current acute exacerbation of chronic inflammatory bowel disease

• Toxic colitis or toxic megacolon

• Ileus and/or acute obstruction or perforation

• Ileostomy

• Right or transverse colostomy

• Subtotal colectomy with ileosigmoidostomy

• 50% of colon removed

• Idiopathic pseudo-obstruction

• History of gastric stapling or bypass procedure

• Difficulties swallowing

• Treatment with an investigational drug or product

• Participation in a drug study within 30 days prior to receiving study medication

• Treatment with another bowel preparation within 21 days prior to colonoscopy

• Known allergy or hypersensitivity to PEG solution